IgA Nephropathy Drug With Novel Mechanism Wins FDA Approval

(MedPage Today) -- The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.
The tablets are indicated...